LAS VEGAS, Dec. 16, 2010 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board : CBAI ), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced in a comprehensive interview with analyst Francis Gaskins that the acquisition of Cyro-Cell Mexico would give CBAI a "clear path to profitability."
The entire interview is available at: http://gaskinsco.com/cbai-12-16-10.mp3 .
Matthew Schissler, CEO, President and co-founder, said Cryo-Cell Mexico has more than 70,000 customers, operates in 32 states in Mexico with 13 affiliates, and has "an impressive, outstanding business model in partnering with hospitals." They are the dominant stem cell storage company in Mexico, and are owned and operated separately from the company with a similar name in the U.S. Cord Blood America on December 8, 2010 announced it has signed a letter of intent to purchase Cryo-Cell Mexico.
"The sales model utilized in Mexico is so good that we would like to utilize it throughout the world," Mr. Schissler said. He said adding this large number of assets should increase the valuation, and market cap, of Cord Blood America. "This acquisition is a game changer for our investors. The large gross profit influx should allow CBAI to operate off its own cash flow after one time acquisition and transitional costs have been normalized."
Cord Blood America's CEO also stressed its three goals for 2011 in the interview. He emphasized capturing more market share and growing organically in the U.S., and in Germany, South America and China, where CBAI has partnerships or owns operating entities; continuing to develop new revenue streams; and operating on its own cash flow.
"These are challenging goals but we have a strong track record of meeting the goals we set for Cord Blood America," Mr. Schissler concluded.
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE Cord Blood America, Inc.